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Background: p53 protein plays an im-
portant role in the response to DNA
damage, and radiotherapy can cause
radiation dermatitis. p53 and p21 levels
increase in vitro when DNA is damaged
by UVA, UVB, or -radiation. To de-
termine whether this response occurs
in human skin and predicts the level of
radiation dermatitis, we investigated
levels of p53 and p21 in skin exposed to
different types of radiation as part of a
randomized study of women with
breast cancer to evaluate topical ste-
roid or emollient cream treatments for
radiation dermatitis of their irradiated
breast . Methods: After surgery
but before receiving tangential 5-mV
photo-beam radiotherapy (2 Gy and
54 Gy) to the affected breast paren-
chyma, multiple areas on the backs of
50 women were irradiated with UVA
and other areas were irradiated with
UVB. Skin biopsy samples were taken
from areas of normal unirradiated skin
and all irradiated areas, and p53 and
p21 were detected immunohistochemi-
cally. All statistical tests are two-sided.
Results: In skin irradiated with UVA
or UVB, medians of 4.4% (range =
0%–40.5%) or 45.5% (range = 5.3%–
74.6%) p53-positive keratinocytes,
respectively, were observed. Radio-
therapy produced medians of 31.0%
(range = 0%–79.3%) p53-immunoreac-
tive cells after 2 Gy of radiation and
83.2% (range = 37.6%–95.2%) after 54
Gy of radiation. Despite large interin-
dividual differences in p53 response,
comparable increases in epidermal p53
response were independent of the type
of radiation. A correlation between p53
and p21 was also evident (rs = .78). In
breast skin, there was no association
between the p53 response and the de-
gree of erythema (a measure of radia-
tion dermatitis) and no statistically sig-
nificant difference between treatment
arms and p21/p53 responses. Conclu-
sions: Individual responses to radia-
tion-induced DNA damage varied widely
and may be independent of the type of
radiation. The epidermal p53 response
does not predict the degree of radiation
dermatitis. [J Natl Cancer Inst 2001;
93:128–33]
p53 and p21, its downstream-effector
protein, are sensitive indicators of DNA
damage. In normal human epidermis,
there are two patterns of p53 immunore-
activity, patch like and diffuse (1–3). The
patch-like pattern represents a cluster of
keratinocytes with a mutated p53 gene
(4–6), and the diffuse pattern is found
in the epidermis after DNA damage has
triggered a reactive accumulation of p53
protein (7,8). p53 accumulates rapidly
in the human epidermis after a single
physiologically active dose of UV radia-
tion. Topical sun-protection lotion applied
before exposure to UV radiation can, in
part, block the epidermal p53 response
(1,9) and, in animal models, the number
of induced p53 mutations are reduced
(10).
UV radiation generates DNA photo-
products, such as pyrimidine dimers and
6-4 photoproducts (11,12). Ionizing irra-
diation produces double- and single-
strand DNA breaks. Cells respond to
DNA photoproducts and DNA breaks by
accumulation of functionally active p53
protein, a key event in response to cellular
stress. Although the initial events and
pathways involved are not completely un-
derstood, increased protein stability re-
sulting in a prolonged half-life appears to
be an important mechanism (13). One
pathway downstream of p53 is mediated
through p21, a general cyclin-dependent
kinase inhibitor. The p21 pathway leads
to cell cycle arrest at the G1 restriction
point caused by decreased phosphoryla-
tion of the retinoblastoma protein (14). If
DNA damage is more severe, p53 is in-
volved in the pathway leading to apop-
totic cell death (15–18). The p53 response
is thus a normal defense mechanism, pro-
tecting an organism from acquiring clones
of mutant cells (19–21). In vitro, a cellu-
lar p53 response has been observed after
-irradiation (18,22), but, to our knowl-
edge, this response has not been studied in
vivo in human skin. That the cellular p53
response can be observed in vivo in ani-
mal models has been shown previously
(23–25).
Unexplained large individual varia-
tions of human skin to UV radiation have
been observed in the p53 response (1) and
the DNA repair reaction (26). An acute
clinical side effect of radiotherapy is ra-
diation dermatitis (27), and large differ-
ences in the degree of radiation dermatitis
have also been noted among individuals
after radiotherapy (28). However, it has
not been determined whether the re-
sponses to UV and ionizing radiation are
related. We address this issue by measur-
ing changes in the levels of p53 and p21
and assessing erythema in the same pa-
tient after exposure to three types of ra-
diation, UVA, UVB, and 5-mV photon-
beam radiation. The study also assessed
the protective effect of a topically applied
steroid on radiation dermatitis, where a
major conclusion was that corticosteroid
cream reduced acute radiation dermatitis
(Bostrom A, Lindman H, Swartling C,
Berne B, Bergh J: manuscript submitted
for publication). In this study, we inves-
tigate interindividual variations in the re-
sponses of p53 and p21 to DNA damage;
analyze the relationships of p53 and p21
with UVA, UVB, and high-voltage pho-
ton-beam irradiation; and determine
whether p53 or p21 would be a good
marker to predict clinical radiation der-
matitis.
PATIENTS AND METHODS
This study was a part of a double-blind random-
ized study that also evaluated the effects of a potent
topical corticosteroid application (mometasone fu-
roate) and placebo (emollient cream) on radiation
dermatitis. The patients received oral and written
information before inclusion in the study.
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Patients
Fifty women with breast cancer between the ages
of 47 and 77 years (mean 59.5 years) entered the
study, which was approved by the ethical committee
with jurisdiction for Uppsala University Hospital,
Sweden. Patients with known cutaneous or severe
systemic disease were excluded. All patients had
been treated by sector resection of a morphologi-
cally verified invasive breast cancer without lymph
node metastasis. No concomitant systemic antican-
cer treatment was administrated. No patient had re-
cently been in the sun or in a tanning bed before
entering the study. All patients were Caucasian and
had the following skin types, according to Fitzpa-
trick (29): 32 patients had skin type 3, 15 had skin
type 2, and three had skin type 4. Patients were
instructed to apply the “blinded” cream to the irra-
diated breast twice a week from the start of the ra-
diotherapy until they had received a total radiation
dose of 24 Gy and then to apply it once a day until
3 weeks after radiotherapy was completed.
Irradiation
Skin on the back of all patients was UV irradiated.
UVB was administered to nine areas (each 7 mm in
diameter) in a stepwise fashion (300–1500 J/m2)
with a monochromator (Applied Photophysics,
Leatherhead, Surrey, U.K.) emitting a narrow band
at 313 nm (±4–6 nm) through a 1-m liquid light
guide with a 7-mm aperture at an irradiance of 15–
17 mW/cm2. UVA was administered with an UVASUN
lamp (Muthzas Co., Munich, Germany) equipped
with a UVA filter (330–450 nm) emitting with an
irradiance of 86 mW/cm2. UVA was delivered to
four areas of skin, each 50 × 50 mm. Each area
received a dose of 10, 20, 40, or 80 J/cm2. Radio-
therapy was started after the UV tests were com-
pleted. All patients received tangential 5-mV pho-
ton-beam radiotherapy to the breast parenchyma, at
2 Gy per visit from a Philips SL 75–5 linear accel-
erator (Philips Inc., Crawley, U.K.) as described pre-
viously (30), for 5 days per week until a total dose of
54 Gy was reached.
Evaluation of Erythema and
Skin Sampling
Degree of UV-induced erythema was determined
from readings 24 hours after irradiation. The follow-
ing scale was used: 0  no erythema; 1  just
perceptible erythema (the minimal erythema dose);
2  mild erythema; 3  marked erythema; 4 
marked erythema and slight edema; 5  marked
erythema and strong edema; and 6  bullous reac-
tion. In addition, the degree of pigmentation after
UVA irradiation was assessed. For UVB, the test
sites that most closely corresponded to a site receiv-
ing twice the minimal erythema dose were subjected
to skin biopsy 24 hours after irradiation. For UVA,
biopsy sites received 40 or 80 J/cm2 (14 patients
received 40 J/cm2 because of a previous medical
history of high sensitivity to UV radiation). Biopsy
samples of normal nonirradiated and irradiated back
skin were taken at the same time, 24 hours after UV
irradiation.
Three breast skin biopsy samples were taken 1 cm
below the areola of the photon-beam-irradiated
breast. The first sample was taken before the start of
radiotherapy, the second was taken 20–30 hours af-
ter the first 2-Gy dose of photon-beam radiation, and
the third was taken immediately after radiotherapy
was completed (total radiation dose 54 or 56 Gy).
Erythema was evaluated, with a reflectance spectro-
photometer, four times during radiotherapy (after
24, 34, 44, and 54 Gy) and 3 weeks after treatment
was completed. The mean of these data, including
data from the five irradiated areas of the breast, was
calculated for each patient and used as an objective
erythema score. Reciprocal areas from the nonirra-
diated breast were used as normal control site.
Skin Biopsy Samples and
Immunohistochemistry
The protocol above resulted in six biopsy samples
(3-mm in diameter) per patient. Ten of these samples
were technically insufficient, leaving a total of 290
interpretable punch biopsy samples. The 3-mm
punch biopsy samples were immediately fixed in
neutral-buffered formalin. After 24–48 hours, the
tissue was embedded in paraffin and 4-m-thick
sections were cut. Immunohistochemistry was per-
formed essentially as described previously (31).
Briefly, sections were cooked in a 750-W micro-
wave oven (two 5-minute periods in 10 mM citric
buffer [pH 6.0]) and stained with avidin–biotin–
coupled immunoperoxidase. An automated stan-
dardized procedure (Ventana Medical Systems Inc,
Tucson, AZ) was used with primary antibodies D-07
(code M7001; dilution 1 : 200; DAKO A/S, Glos-
trup, Denmark), which reacts with both wild-type
and mutant human p53 protein, and WAF-1 (Ab-1,
dilution 1 : 40; Oncogene Research Products from
CALBIOCHEM, Cambridge, MA), which reacts
with human p21 protein. Sections were counter-
stained with Mayer’s hematoxylin.
Scoring of p53 and p21
Immunoreactivity
Sections of immunostained skin were evaluated
under the microscope by one person (Dr. Christina
Nyberg, University Hospital, Uppsala, Sweden). All
epidermal keratinocyte nuclei from four randomly
chosen high-power fields, covering more than 50%
of the total epidermal length in each biopsy sample,
were evaluated and counted. In anti-p53-stained
sections, the difference between nonimmunoreactive
and immunoreactive keratinocyte nuclei was clear-
cut, and cells were scored as positive or negative.
Anti-p21-stained sections showed gradients of reac-
tivity, rendering binary assessment impossible.
Consequently, the proportion of immunohistochem-
ically positive cells was estimated on the following
scale of 1–4: 1  less than 25% immunoreactive
keratinocytes; 2  25% to 50% immunoreactive
keratinocytes; 3  50% to 75% immunoreactive
keratinocytes; and 4  more than 75% immunore-
active keratinocytes. This modified scale was moti-
vated by a diffuse reaction pattern for the p21 anti-
body. The intensity of the p21 immunoreaction was
determined as weak, moderate, or strong.
Methods for Statistical Analysis
This study did not have the statistical power to
investigate possible differences in local and sys-
temic relapse frequencies. It would, of course, have
been ideal to have a larger study population to be
able to investigate whether the p53 activation pattern
in the normal skin of a cancer patient is associated
with the p53 response status in the same patient’s
tumor cells.
Nonparametric methods were used for the statis-
tical analysis. The Spearman’s rank correlation test
was used to calculate potential correlations. The cor-
responding correlation coefficient is denoted rs in
the text. Because multiple correlation analyses were
performed, only P values of less than .01 were con-
sidered to be statistically significant. For compari-
son of two groups, the Mann–Whitney U test was
used. All statistical tests are two-sided.
RESULTS
The average number of cells counted
per anti-p53-stained biopsy sample was
528. Skin type did not influence p53 im-
munoreactivity in nonirradiated or irradi-
ated skin. Table 1 shows a summary of
the mean percentage of p53-positive cells
and p21 score. Fig. 1 shows p53 immu-
noreactivity in the following six groups:
1) normal back skin, 2) normal breast
skin, 3) UVA-irradiated back skin, 4)
UVB-irradiated back skin, 5) 2 Gy of
photon-beam-irradiated breast skin, and
6) 54 Gy of photon-beam-irradiated
breast skin. Table 2 shows correlations in
p53 immunoreactivity between the differ-
ent groups.
Nonirradiated Skin
In general, breast skin was slightly
thinner than back skin. The number of ke-
ratinocytes, however, did not differ statis-
tically significantly between back (mean
 618 keratinocytes; range  427–936
keratinocytes) and breast (mean  583
keratinocytes; range  384–938 kera-
tinocytes) skin. A few scattered p53-
positive keratinocytes were present in 41
of the 50 biopsy samples from normal
breast (Fig. 2, a) and 43 of the 49 from
back skin (Fig. 2, b). p53-positive kera-
tinocytes were 2.3% of cells (median 
1.2%; range 0%–31.1%) in breast skin
and 1.8% (median 1.3%; range 0%–
8.9%) in back skin. In one patient (No.
30), 31.1% of nuclei of the unirradiated
breast skin were p53 positive. Only a few
keratinocytes showed weak p21 staining.
Photon-Beam Radiotherapy
Compared with nonirradiated skin, no
changes were detected by light micros-
copy in skin biopsy samples taken after
the patient had received 2 Gy of photon-
beam radiation. However, severe morpho-
logic changes, similar to what has been
described previously (32), were observed
(Fig. 2, d) in biopsy samples taken after
radiotherapy was completed (total dose
 54 Gy). The epidermis in these
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samples was thin, containing only one to
three layers of keratinocytes, and the ke-
ratinocytes were enlarged with cytologic
atypia. The dermis had dilated capillaries
and a partly perivascular chronic inflam-
matory infiltrate. Immunohistochemical-
ly, 30.1% (median  31.0%; range 
0%–79.3%) of the keratinocytes were
positive for p53 after 2 Gy of irradiation
(Fig. 2, c). There were fewer than 25%
p21-positive cells (score  1.1), and the
intensity of p21 staining was weak. The
most widespread, intense, and uniform
staining for p53 and p21 was observed in
skin that had received 54 Gy of irradia-
tion. After radiotherapy was completed,
80.1% (median  83.2%; range 
37.6%–95.2%) of keratinocytes were p53
positive (Fig. 2, d). In most cases, 75% or
more of the keratinocytes (score  3.4)
showed a moderate-to-strong intensity of
p21 staining. Objective measurements of
erythema varied between scores of 2.3
and 11.2 (mean score  6.4).
UVA Irradiation
No morphologic changes were found
in skin after UVA irradiation compared
with nonirradiated skin. In UVA-irradiated
skin, 7.4% (median  4.4%; range 
0%–40.5%) of the keratinocytes overex-
pressed p53 (Fig. 2, e). p53 immunoreac-
tivity did not differ statistically signifi-
cantly between patients irradiated with 40
J/cm2 and patients irradiated with 80
Table 1. p53- and p21-immunoreactive cells in normal and irradiated skin*
Value (95% CI)
Nonirradiated skin
Back skin
% p53 positive 1.8 (1.3 to 2.3)
p21 score 0.7 (0.6 to 0.9)
Breast skin
% p53 positive 2.3 (1.0 to 3.5)
p21 score 0.6 (0.5 to 0.7)
Irradiated skin
UVA, 68.8 J/cm2 on back skin
% p53 positive 7.4 (5.2 to 9.6)
p21 score 0.9 (0.8 to 1.0)
UVB, 628 J/m2 on back skin
% p53 positive 45.2 (40.3 to 50.1)
p21 score 2.6 (2.2 to 2.9)
Emollient treated
Value (95% CI)
Topical steroid
Value (95% CI)
Treated skin
Photon beam, 2 Gy on breast skin
% p53 positive 31.6 (21.8 to 41.4) 28.5 (19 to 38)
p21 score 1.1 (0.8 to 1.3) 1.0 (0.9 to 1.1)
Photon beam, 54 Gy on breast skin
% p53 positive 77.0 (70.7 to 83.3) 83.3 (78.8 to 87.8)
p21 score 3.3 (2.9 to 3.7) 3.5 (3.1 to 3.8)
Erythema score (breast skin) 7.5 (6.7 to 8.3) 5.4 (4.8 to 6.0)
*For normal and irradiated skin, the mean percentage (including 95% confidence interval [CI]) of p53-
immunoreactive cells is shown. The mean score (including 95% CI) for the number of p21-positive cells is
also shown (scores: 1  <25%; 2  25%–50%; 3  >50%–75%; and 4  >75% immunoreactive
keratinocytes). The location for the skin biopsy sample and the mean administered UVA and UVB dose are
shown. Mean values for breast skin treated with photon-beam radiation are split in the two treatment groups
(topical steroid cream and emollient cream). There was a marked interindividual heterogeneity in the number
of p53-positive cells in the various irradiated and nonirradiated samples. Erythema scores were lower in
patients treated with topical steroids than in those treated with only moisturizer, but no statistically significant
difference was observed in p53 immunoreactivity after completed radiotherapy (54 Gy) in these groups. No
statistically significant difference was found between use of topical steroids and moisturizer with respect to
the p53/p21 response of epidermal keratinocytes to high-voltage photon-beam radiation (2 Gy, P  .59;
54 Gy, P  .23). All statistical tests were two-sided. A supplementary table containing an overview of the
data from the 50 patients in this study can be found as an on-line supplement on the Journal’s web site
<http://www.jnci.oupjournals.org>.
Fig. 1. p53 immunoreactivity in the
following six groups: normal back
skin, normal breast skin, and UVA-,
UVB-, 2 Gy of photon-beam-, and 54
Gy of photon-beam-irradiated skin.
Bars represent the range within the
different groups as indicated. The
box plots for 2 Gy and 54 Gy of ra-
diation have been split by topical
treatment.
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J/cm2. Fewer than 25% of keratinocytes
were p21 immunoreactive (mean score
0.9), and the intensity of p21 staining was
weak.
UVB Irradiation
The administered dose of UVB (300–
1500 J/m2) depended on the patient’s sen-
sitivity to UVB (i.e., the minimal erythe-
ma dose), which did not correlate directly
with the patient’s skin type (rs  .21).
There was no clear correlation between
the physical UVB dose and the number of
p53-positive cells observed (rs  .28).
Morphologic changes (i.e., epidermal
edema, sunburned cells, and dermal in-
flammation) were observed in UVB-
irradiated skin compared with nonirradi-
ated skin, 45.2% (median  45.5%;
range  5.3%–74.6%) of keratinocytes
were p53 positive (Fig. 2, f), and in-
creased p21 expression with a moderate-
to-strong intensity was found in approxi-
mately 50% of the cells (score  2.6).
We have not, in our initial aims, ana-
lyzed the topographic distribution of p53
immunoreactivity in different layers of
the epidermis. However, the five cases
with strongest p53 reaction to UVA and
to 2 Gy, as well as the five with the weak-
est reaction, were reviewed to examine
eventual differences in expression pat-
terns. We found that UVA resulted in p53
immunoreactivity within all epidermal
layers with relatively more positivity
within the basal cell layer when compared
with UVB. The expression pattern for 2
Gy and UVA showed a similar pattern,
i.e., positivity within all nucleated levels
of epidermis with a tendency to a relative
increase in basal cells. In skin irradiated
with 54 Gy, the epidermis was severely
altered without differences in p53 immu-
noreactivity in basal or suprabasal cells.
Similar to what is known for UV ra-
diation, ionizing radiation did not lead to
p53 immunoreactivity in mesenchymal
cells of the dermis. Only rare p53-positive
dermal cells were seen after 54 Gy of ra-
diation.
DISCUSSION
The major finding in this study was the
close correlation between p53 expression
after photon-beam radiotherapy and UV
irradiation, especially with UVB irradia-
tion (rs  .61). The large number of pa-
tients (50 patients) and multiple biopsy
sites (six sites) also permitted an over-
view of interindividual variations in nor-
mal skin and sensitivity to different sources
of radiation. The long-term goal with this
project was to gain insight into the differ-
ences in radiation sensitivity in normal
tissues so that therapies can be tailored
specifically for each individual and also
to understand the value of topical steroid
for protection of radiation dermatitis.
After UV radiation-induced DNA
Table 2. Correlations
a. Correlations before treatment*
Subjects
(n  50)
Variable 1,
irradiation Variable 1, sample Variable 2
Correlation,
rs P
All Baseline Back p53% versus Breast p53% .58 <.001
All Baseline Back p53% versus UVA p53% .37 .011
All Baseline Back p53% versus UVB p53% .40 .005
All Baseline Breast p53% versus 2 Gy p53% .47 .001
All UVA Back p53% versus UVB p53% .44 .002
All UVA Back p53% versus 2 Gy p53% .50 <.001
All UVB Back p53% versus 2 Gy p53% .61 <.001
b. Correlations after placebo treatment†
Subjects
(n  25)
Variable 1,
irradiation Variable 1, sample Variable 2
Correlation,
rs P
Placebo Baseline Breast p53% versus 54 Gy p53% .28 .2
Placebo Baseline Breast p53% versus Erythema .34 .09
Placebo UVA Back p53% versus 54 Gy p53% .21 .3
Placebo UVA Back p53% versus Erythema .09 .7
Placebo UVB Back p53% versus 54 Gy p53% .40 .05
Placebo UVB Back p53% versus Erythema .20 .3
Placebo 2 Gy Breast p53% versus 54 Gy p53% .46 .03
Placebo 2 Gy Breast p53% versus Erythema −.0025 1.0
Placebo 54 Gy Breast p53% versus Erythema −.17 .4
c. Correlations after cortisone treatment†
Subjects
(n  24)
Variable 1,
irradiation Variable 1, sample Variable 2
Correlation,
rs P
Cortisone Baseline Breast p53% versus 54 Gy p53% .021 .9
Cortisone Baseline Breast p53% versus Erythema −.14 .5
Cortisone UVA Back p53% versus 54 Gy p53% .18 .4
Cortisone UVA Back p53% versus Erythema −.33 .1
Cortisone UVB Back p53% versus 54 Gy p53% −.06 .8
Cortisone UVB Back p53% versus Erythema −.52 .008
Cortisone 2 Gy Breast p53% versus 54 Gy p53% .16 .5
Cortisone 2 Gy Breast p53% versus Erythema −.038 .9
Cortisone 54 Gy Breast p53% versus Erythema −.16 .4
*a: Nonparametric correlations of p53 immunoreactivity before radiotherapy and after 2 Gy of 5 mV
photon-beam radiotherapy to the breast. Data from all 50 patients were used for this calculation. Both
Spearman’s rank coefficient of correlation (rs) and the corresponding P value are shown; all statistical tests
are two-sided. In all studied groups, there was a statistically significant correlation between p53 and p21
immunoreactivity. When we compared all skin samples (n 290), a very good correlation between p53 and
p21 was seen (rs .78; P<.001). There was a strong association between the number of p21-immunoreactive
cells and the intensity of the p21 reaction. Within-individual p53 immunoreactivity correlated irrespective of
whether samples were from nonirradiated, UVA-irradiated, UVB-irradiated, or 2-Gy-irradiated skin. In
nonirradiated skin, the number of p53-positive back skin cells correlated with the number of p53-positive
cells in breast skin (rs  .58; P<.001). There was also a positive correlation among nonirradiated skin and
skin irradiated with UVA, UVB, and 2-Gy photon-beam radiation. There was a clear and statistically
significant correlation between p53 immunoreactivity in UVA-irradiated skin and UVB-irradiated skin (rs
.44; P .002) and between UVA-irradiated skin and skin that had received 2 Gy of photon-beam irradiation
(rs .50; P<.001). The strongest correlation was between p53 immunoreactivity in UVB-irradiated skin and
2-Gy photon-beam irradiated skin (rs  .61; P<.001). In samples taken from skin irradiated with 54 Gy of
photon-beam irradiation, p53 and p21 immunoreactivities were consistently stronger and were not statisti-
cally significantly correlated with immunoreactivities in other samples.
†b and c: Nonparametric correlations for both breast erythema and p53 immunoreactivity after radio-
therapy was completed in the group of 25 emollient-treated patients and in the topical steroid group of 24
patients. Analyzing the steroid-treated groups and non-steroid-treated patient groups separately could only
identify a weak correlation in the p53 reactions after 54 Gy of photon-beam radiation compared with after
2 Gy of radiation and UVB in the non-steroid-treated group. The average objective erythema of the breast
showed no correlation to p53 or p21 immunoreactivity in any calculation, except for the negative correlation
to UVB in the steroid-treated group. Because the group of emollient-treated patients showed an opposite but
very weak correlation, the analysis of UVB versus erythema for all patients did not reveal any correlation
(rs  −.18; P  .2).
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damage (1,8), p53 and p21 proteins have
been detected in higher than normal levels
in the epidermis, and we have demon-
strated individual differences in the ex-
pression of p53 protein after exposure to
sunlight (9). Interindividual differences in
the radiosensitivity of human skin have
been detected with clinical end points
(28), and the effects of ionizing radiation
on human skin have also been studied, in
part (33). However, to our knowledge, the
expression of p53 and p21 during and af-
ter radiotherapy has not been analyzed.
We observed that, after 2 Gy of pho-
ton-beam radiation, the p53 response in
epidermis showed the same large interin-
dividual variation as UV-irradiated skin.
Aside from skin repeatedly subjected to
5-mV photon-beam irradiation (total dose
 54 Gy), where most (80%) of the ke-
ratinocytes were p53 positive, UVB irra-
diation provoked the strongest response;
approximately half (45%) of the epider-
mal cells were strongly immunoreactive
for p53. In addition, we observed that
only 2 Gy of photon-beam irradiation
caused a substantial p53 response (30%)
and that UVA irradiation only caused a
relatively mild response (7%). The p53
responses induced by different types of
radiation might be caused by variations in
DNA damage associated with wavelength-
related differences in absorption. Alterna-
tively, different types of radiation could
trigger different p53 activation pathways,
in a manner independent of the degree of
DNA damage.
It should be noted that a patient with a
strong reaction to UVA will tend to react
strongly to UVB and photon-beam (2 Gy)
irradiation and vice versa. Although the
correlation is strongest between UVB and
photon-beam (2 Gy) irradiation (rs 
.61), there appears to be a general intrin-
sic variation in the general p53 respon-
siveness. The molecular reasons for this
interindividual variation are unclear;
however, large interindividual differences
have also been shown in repair of cy-
clobutane pyrimidine dimers and 6-4
photoproducts in human skin exposed to
solar-simulating radiation (26). There
does not appear to be a simple association
of skin type and p53 or p21 response. All
patients received the same dose of radio-
therapy (2 Gy), and the p53 response did
not correlate with skin type (rs  .12).
The doses of UVA and UVB radiation
that were given were determined because
of different clinical responses and did not
clearly correlate with the intensity of the
p53 response (UVA rs .11; UVB rs
.28). Samples from UVB-irradiated skin
were taken from areas subjected to double
the minimal erythema dose, which re-
sulted in a “just perceptible erythema”
(2). UV radiation causes thymine dimers
and 6-4 photoproducts in DNA; thus,
DNA has been proposed as the chromo-
phore for erythema (34). However, there
is no simple association between the UV
radiation-induced increased levels of p53
in epidermis and clinical erythema (35).
Skin irradiated with a total of 54 Gy was
severely damaged and had strong p53 and
p21 responses. Eventually, individual
variations are probably masked by the se-
vere damage caused by large amounts of
ionizing radiation. The p21 response, in
general, mirrored the p53 response, in
agreement with the hypothesis that, after
DNA damage, p53 induces p21. In gen-
eral, when there was a strong p53 re-
sponse (UVB and especially 54 Gy of
photon-beam radiation), there was a strong
p21 response. However, skin that had re-
ceived only 2 Gy of photon-beam radiation
had a weaker p21 response than would be
expected from the p53 response. The ex-
planation for this observation is unclear.
In this study, we show that a few scat-
tered p53-positive cells (approximately
2%) are present in normal, previously
sun-exposed back skin and nonexposed
breast skin. Although some patients may
have an early history of sun exposure to
the breasts, we assume that breast skin of
most women in the age group studied
(47–77 years old) has not been exten-
Fig. 2. Immunohistochemically
stained sections of skin, displaying
the various layers of the epidermis
and the upper part of underlying der-
mis. The p53 antibody from one pa-
tient who showed a strong p53 re-
sponse was used. Immunoreactive
keratinocyte nuclei are brown, and
nonimmunoreactive nuclei are
stained blue with hematoxylin. Nor-
mal, nonirradiated breast skin (a) and
back skin (b) have a few scattered
keratinocytes with various levels of
p53 immunoreactivity. Twenty-four
hours after 2 Gy of high-voltage pho-
ton-beam irradiation, an increased
number of p53 immunoreactive cells
are seen in the epidermis (c). After
radiotherapy was completed (54 Gy),
the epidermis is severely damaged,
and keratinocytes show strong p53
immunoreactivity (d). Twenty-four
hours after UV irradiation, epidermal
keratinocytes show an elevated p53
response (e). UVA  80 J/cm2. (f)
UVB  600 J/m2. Scale bar for all
panels  120 m.
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sively exposed to the sun. The p53-
positive cells have not been characterized.
These cells could represent single cells
that have acquired a p53 mutation, not
sufficient to cause clonal expansion,
which is so commonly found in chroni-
cally sun-exposed skin (4,5,36). The use
of laser microdissection, gene amplifica-
tion, and DNA sequencing of single cells
(37) would be an important tool to spe-
cifically analyze these cells.
In summary, large interindividual dif-
ferences were observed in the radiation-
induced p53 response in human skin that
is independent of the type of radiation
used. The p53 response did not reflect the
individual radiation erythema. The bio-
logic importance of being a weak or a
strong p53 responder is not known. The
mechanisms regulating the increase in
p53 in vivo in response to cellular damage
and the role of p53-positive cells in normal
nonirradiated skin need additional study.
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